Halo Pharma

Overview

Halo Pharma is a contract development and manufacturing organization (CDMO) specializing in small molecule pharmaceutical development and commercial manufacturing. The company serves pharmaceutical innovators, generic manufacturers, and OTC product owners with end-to-end capabilities spanning formulation development, analytical testing, clinical supply manufacturing, and commercial-scale production.

Services & Capabilities

Development & Analytical

• Formulation development (non-GMP and cGMP)
• Analytical testing and method development
• Process development
• Quality assurance and testing

Manufacturing & Dosage Forms

• Solid dosage forms (tablets, capsules)
• Semi-solid formulations (creams, ointments, gels)
• Oral liquid formulations
• Sterile injectable manufacturing (vials, prefilled syringes, cartridges) — operational in 2026
• Fill-finish platform capabilities

Accelerated Programs

• Accelerated Tech Transfer Program: fixed-scope, set-price engagement transitioning clinical-stage or transferred programs to GMP manufacturing in 16–20 weeks

Facilities

Whippany, New Jersey

• Non-GMP and cGMP formulation development through commercial manufacturing
• Expanding sterile injectable capabilities (2026)

Mirabel, Quebec, Canada

• Non-GMP and cGMP pharmaceutical development and commercial manufacturing

Market Position

Halo emphasizes speed, agility, quality, and timeliness across two North American state-of-the-art facilities. The company positions itself as a trusted partner for bringing small molecule therapeutics to market expeditiously without compromising safety and quality.